Evolus Delivers Q1 Profitability, Reaffirms 2026 Outlook; Cash Conversion Still the Key Test

What happened

Evolus reported Q1 2026 revenue and a second consecutive quarter of positive Adjusted EBITDA, demonstrating continued cost discipline in a seasonally weak period. Management reaffirmed the full-year 2026 revenue guidance of $327M-$337M, relying on Jeuveau share gains and the HA filler ramp to offset a mid-single-digit royalty through 2032. However, the press release lacked detail on gross margin trajectory and operating cash flow, which are critical to validating the sustainability of profitability beyond Q4 seasonality. The master report highlights that cash burn remains a risk, with 9M'25 operating cash flow of -$55.1M, and the stock at ~1.0x FY2026 revenue leaves little room for error. The coming quarters must show that the cost reset is durable and that HA filler mix (targeting 10-12% of revenue) is on track to avoid the need for dilutive financing.

Implication

The reaffirmed guidance and second consecutive quarter of profitability support the thesis that Evolus can achieve sustainable profitability in FY2026, reducing the need for capital raises. However, the structural royalty and competitive pricing pressure mean the stock's upside is capped until cash flow improves materially. The key test will be Q2 results, which should show non-seasonal profitability and cash generation to validate the investment case.

Thesis delta

The Q1 results increase confidence in the profitability path, but the market already priced in this narrative (stock ~$4.30). The key change is that the company is executing on its cost reset and HA ramp, but the lack of detail on gross margin and cash flow in the press release leaves significant uncertainty. The thesis shifts from 'wait for profitability proof' to 'proof is emerging but incomplete; re-evaluate when Q2 results show non-seasonal profitability.'